Picture of OptiBiotix Health logo

OPTI OptiBiotix Health News Story

0.000.00%
gb flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapNeutral

REG - OptiBiotix Health - Commercial update

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230829:nRSc5247Ka&default-theme=true

RNS Number : 5247K  OptiBiotix Health PLC  29 August 2023

OptiBiotix Health plc

("OptiBiotix" or the "Company")

 

Commercial update

 

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing
compounds to tackle obesity, high cholesterol, diabetes and skincare,
announces that further to the recent overview of its SweetBiotix® product
range announced on 19 July 2023, the Company provides an overview of
commercial progress of its first-generation products range.

 

The Company reports an update on commercial activities in 2023 to date:-

 

I.     The Company achieved its highest ever own brand online sales in
July 2023. Online sales growth has been helped by an improved website,
checkout and logistics leading to a 450% increase in the online conversion
rate (number of sales divided by number of visitors to site), and the opening
up of new online channels such as Amazon. We now have listings of SlimBiome®
Medical and Gofigure® products on Amazon UK and Amazon Prime, Slimbiome®
Medical on Amazon Germany (to be followed by Amazon Prime) and Walmart USA. We
are going through the extensive process of listing products on Amazon India,
Amazon UAE, and Amazon USA as part of the online internationalisation of our
own brand products and investment in marketing to support further sales
growth.

 

II.    One of our partners has secured an international listing for
products containing SlimBiome® with Costco, the fifth largest retailer in the
world.  Discussions are ongoing to determine launch plans in a number of
territories around the world.  Further details will be provided as products
are launched in different countries.

 

III.   The Company has received a large initial order from a new partner
of £116K for SlimBiome® from a contract manufacturer of a leading weight
management and sports nutrition brand in the USA. The company plans to launch
in Europe in 2023 followed by a 2024 launch in the USA.  Launch plans have
high commercial sensitivity and further information will be provided when
approved by the partner.

 

IV.  We have signed agreements with four new partners in Asia for SlimBiome®
since April who have all placed orders.  These include Nasol Pharma
International (Vietnam), Bonanaza Neutra Thailand), Colorinda Chemtra
(Indonesia), and NexusWise (Malaysia and Singapore). These are all well-known
specialist distributors in their field of expertise and are reporting strong
interest in SlimBiome.

 

V.    The Company launched its health and wellbeing WellBiome® functional
fibre and mineral blend in May 2023 as part of a strategy to enhance its range
of product offerings.  The product has received excellent reviews on Amazon
with growing month on month sales (125% increase July to August) and a high
number of repeat orders (63% in August).   As we move into the Autumn we
will increase our marketing on WellBiome® and extend its availability to
other Amazon international channels.

Stephen O'Hara, CEO of OptiBiotix Health plc said: "We are making good
progress on our aims of getting existing partners returning to forecast,
bringing in new partners, particularly in the USA and Asia, and expanding
e-commerce channels to grow online sales and reduce partner dependency. This
is all part of plans for each business unit (USA, India, Ecommerce, B2B) to
reach operational profitability, at least on a monthly basis by the end of the
calendar year.

 

"The aim for the second half of the year is to continue our focus on managing
costs, growing sales and closing out ongoing discussion with a number of
larger partners across first and second generation products to ensure a return
on investment from our expansion in our commercial and business development
team."

 

This announcement contains information which, prior to its disclosure, was
considered inside information for the purposes of the UK Market Abuse
Regulation and the Directors of the Company are responsible for the release of
this announcement.

 

Forward-Looking Statements

Certain statements made in this announcement are forward-looking statements.
These forward-looking statements are not historical facts but rather are based
on the Company's current expectations, estimates, and projections about its
industry; its beliefs; and assumptions. Words such as 'anticipates,'
'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar
expressions are intended to identify forward-looking statements. These
statements are not guarantees of future performance and are subject to known
and unknown risks, uncertainties, and other factors, some of which are beyond
the Company's control, are difficult to predict, and could cause actual
results to differ materially from those expressed or forecasted in the
forward-looking statements. The Company cautions security holders and
prospective security holders not to place undue reliance on these
forward-looking statements, which reflect the view of the Company only as of
the date of this announcement. The forward-looking statements made in this
announcement relate only to events as of the date on which the statements are
made. The Company will not undertake any obligation to release publicly any
revisions or updates to these forward-looking statements to reflect events,
circumstances, or unanticipated events occurring after the date of this
announcement except as required by law or by any appropriate regulatory
authority.

 

For further information, please contact:

 

 OptiBiotix Health plc                             www.optibiotix.com (http://www.optibiotix.com/)
 Neil Davidson, Chairman  Contact via Walbrook below
 Stephen O'Hara, Chief Executive

 Cairn Financial Advisers LLP (NOMAD)              Tel: 020 7213 0880
 Liam Murray / Jo Turner / Ludovico Lazzaretti

 Peterhouse Capital Limited (Broker)               Tel: 020 7220 9797
 Duncan Vasey / Lucy Williams

 Walbrook PR Ltd                                   Mob: 07876 741 001
 Anna Dunphy

 

About OptiBiotix - www.optibiotix.com (http://www.optibiotix.com/)

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings
science to the development of compounds which modify the human microbiome -
the collective genome of the microbes in the body - in order to prevent and
manage human disease and promote wellness.

 

OptiBiotix has an extensive R&D programme working with leading academics
in the development of microbial strains, compounds, and formulations which are
used as active ingredients and supplements. More than twenty international
food and healthcare supplement companies have signed agreements with
OptiBiotix to incorporate their human microbiome modulators into a wide range
of food products and drinks.

 

OptiBiotix is also developing its own range of consumer supplements and health
products. The Company's current areas of focus include obesity, cardiovascular
health, and diabetes.

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDQELFLXVLXBBF

Recent news on OptiBiotix Health

See all news